

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Statement for Form 1489PT0

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary.)

Sheet 1

1

Attorney Docket Number PC17370

Application Number	10/647,358
Filing Date	August 25, 2003
First Named Inventor	Charles L. Bisgaier, et al.
Art Unit	1816
Examiner Name	John Pak
Attorney Docket Number	PC17370

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Case No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code* "Number" "Kind Code" (if known)	MM-DD-YYYY		Y*
		EP0401705A2 (Corresp to JP2003-20226)	12-12-1990	E. R. Squibb & Sons Inc	
		JP2002-608320A (Corresp to WO1999/30704)	03-19-2002	Warner-Lambert Company	
		JP03-20226A (Corresp to EP0401705)	01-29-1991	E. R. Squibb & Sons Inc	
		WO1996/30328A1	10-03-1996	Warner-Lambert Company	
		WO1997/38694A1	10-23-1997	Merck & Co Inc	
		WO1999/30704A1 (Corresp to JP2002-50832)	06-24-1999	Warner-Lambert Company	

EXAMINER: Indicate if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Indicate copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional)." See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST.5). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. "Kind of document by the two-letter code as indicated on the document under WIPO Standard ST.19 if possible. "Applicant is to place a check mark here if English language transcription is attached to the document." *(This block is repeated for each reference citation.)*

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (lead by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and sending the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or suggestions you may have regarding this collection of information, including suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-270-0198 (1-800-729-0198) and select option 2.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2 Attorney Docket Number PC17370

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Complete if Known
		AVIRAM, et al., "Interaction of Oxidized Low Density Lipoprotein with Macrophages in Atherosclerosis, and the Antithromboticity of Antioxidants", Eur J Clin Chem Clin Biochem, 1996, pp 599-608, Vol. 34	T ²
		GRUNDY S. M., et al., "Atherogenic Dyslipidemia: Lipoprotein Abnormalities and Implications for Therapy", Amer J Cardiology, 1996, Vol. 75, pp 458-528	
		HEINONEN T. M., et al., "Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol", J Cardio Pharm Therap, 1996, pp 117-122, Vol.1, No.2	
		ILLINGWORTH D. R., et al., "Comparative Effects of Lovastatin and Niacin in Primary Hypercholesterolemia, Arch Internal Med, 1994, pp 1588-1595, Vol.154, No.14	
		JONES P. H., et al., "Effect of gemfibrozil on level of lipoprotein (a) in Type II hyperlipoproteinemic subject, J Lipid Res, 1996, pp 1298-1308, Vol. 37	
		SHIOMI M., et al., "Suppression of established atherosclerosis and xanthomas in immature WHHL rabbits by keeping their serum cholesterol levels extremely low", Atherosclerosis, 1990, pp 69-80, Vol.83	
		STONE N. J., et al., "Lipid Management: Current Diet and Drug Treatment Options," Amer J Med, 1996, pp 4A40S-4A49S, Vol.101 (suppl 4A)	

Examiner Signature

Date Considered

7/9/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. This will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.